Skeletal muscle proteins

Skeletal muscle proteins constitute a diverse group of structural and functional molecules essential for voluntary movement, posture, and metabolic homeostasis. This broad category includes the contractile apparatus, primarily actin and myosin, regulatory proteins such as the troponin complex and tropomyosin, and massive structural proteins like titin and dystrophin (UniProt, 2024; StatPearls, 2023). These proteins work in concert to convert chemical energy from ATP into mechanical force through the sliding filament mechanism, a process tightly regulated by intracellular calcium levels. Dysregulation, genetic mutations, or autoimmune attacks on these proteins underlie various neuromuscular disorders, including Duchenne muscular dystrophy and myasthenia gravis (NIH, 2022). While specific proteins within this group, such as the ryanodine receptor or fast skeletal muscle troponin, are targeted by drugs like dantrolene or reldesemtiv, the term 'Skeletal muscle proteins' is a collective classification rather than a single therapeutic target. Consequently, it is often considered too broad for precise pharmacological profiling in drug discovery contexts.

Other names

Myofibrillar proteinsContractile proteinsSarcoplasmic proteinsMuscle fiber proteins

Drugs interacting with skeletal muscle proteins typically function by modulating neuromuscular transmission at the nicotinic acetylcholine receptor, regulating calcium release via the ryanodine receptor, or sensitizing the troponin complex to calcium to enhance contractility (StatPearls, 2023; PubMed, 2021).